---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-102314"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T12:47:07.378299+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vericel launches NexoBrid in U.S. for severe thermal burns; $300M addressable market

## Summary
- Full commercial launch of NexoBrid for eschar removal in adults with deep partial/full-thickness thermal burns.
- Selective enzymatic debridement preserves viable tissue vs. surgical excision.
- Addressable U.S. market of ~30,000 patients/year, equating to $300 million.
- Product can be applied in up to two 4-hour sessions covering up to 20% total body surface area.
- Launch expands Vericel's Burn Care franchise and diversifies revenue stream.

## SEC filing metadata
- accession: 0001104659-23-102314
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000110465923102314/0001104659-23-102314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000110465923102314/tm2326562d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-102314
- JSON: https://secwatch.observer/filing/0001104659-23-102314.json
- Plain text: https://secwatch.observer/filing/0001104659-23-102314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.